Last updated on June 2018

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia


Brief description of study

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia

Detailed Study Description

Study CC-90009-AML-001 is an open-label, Phase 1, dose escalation and expansion, first-in-human clinical study of CC-90009 in subjects with relapsed or refractory acute myeloid leukemia (AML).

The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-90009, The expansion part (Part B) will further evaluate the safety and efficacy of CC-90009 administered at or below the maximum tolerated dose (MTD) in selected expansion cohorts of in order to determine the recommended Phase 2 dose (RP2D).

Clinical Study Identifier: NCT02848001

Contact Investigators or Research Sites near you

Start Over

Associate Director Clinical Trial Disclosure

Yale Cancer Center
New Haven, CT United States
  Connect »

Associate Director Clinical Trial Disclosure

Northwestern Memorial
Chicago, IL United States
  Connect »

Associate Director Clinical Trial Disclosure

Dana Farber Cancer Institute
Boston, MA United States
  Connect »

Associate Director Clinical Trial Disclosure

Washington University Siteman Cancer Center
Saint Louis, MO United States
  Connect »

Associate Director Clinical Trial Disclosure

Hackensack University Medical Center
Hackensack, NJ United States
  Connect »

Associate Director Clinical Trial Disclosure

Princess Margaret Hospital University Health Network
Toronto, ON Canada
  Connect »

Associate Director Clinical Trial Disclosure

Institut Paoli Calmettes
Marseille Cedex 9, France
  Connect »

Associate Director Clinical Trial Disclosure

Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie
Villejuif, France
  Connect »

Associate Director Clinical Trial Disclosure

Spedali Civili Di Brescia
Brescia, Italy
  Connect »

Associate Director Clinical Trial Disclosure

A.O. Ospedale Ca Granda - Niguarda
Milano, Italy
  Connect »

Associate Director Clinical Trial Disclosure

Beatson West of Scotland Cancer Centre
Glasgow Scotland, United Kingdom
  Connect »

Associate Director Clinical Trial Disclosure

The Churchill Hospital
Oxford, United Kingdom
  Connect »

Associate Director Clinical Trial Disclosure

City of Hope
Duarte, CA United States
  Connect »

Associate Director Clinical Trial Disclosure

Haukeland University Hospital
Bergen, Norway
  Connect »

Associate Director Clinical Trial Disclosure

Oslo University Hospital, Rikshospitalet HF
Oslo, Norway
  Connect »

Associate Director Clinical Trial Disclosure

H Clinic I Provincial
Barcelona, Spain
  Connect »

Associate Director Clinical Trial Disclosure

Hospital Clinico Universitario de Salamanca
Salamanca, Spain
  Connect »

Associate Director Clinical Trial Disclosure

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »